Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study

被引:4
|
作者
Ullah, Asad [1 ]
Saeed, Omer [2 ]
Karki, Nabin Raj [3 ]
Goodbee, Mya [4 ]
Yasinzai, Abdul Qahar Khan [5 ]
Waheed, Abdul [6 ]
Heneidi, Saleh [7 ]
Thomas, Anish [8 ]
Karim, Nagla Abdel [9 ]
Johnson, Joyce [1 ]
Del Rivero, Jaydira [8 ]
Khan, Jaffar [2 ]
机构
[1] Vanderbilt Univ Sch Med, Dept Pathol, Nashville, TN 37232 USA
[2] Indiana Univ, Indiana Sch Med, Dept Pathol, Indianapolis, IN 46202 USA
[3] Univ S Alabama, Dept Hematol & Oncol, Mobile, AL 36688 USA
[4] Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA
[5] Bolan Med Coll, Dept Med, Quetta 83700, Pakistan
[6] San Joaquin Gen Hosp, Dept Surg, San Joaquin, CA 95231 USA
[7] Cedars Sinai Med Ctr, Dept Mol Pathol, Los Angeles, CA 90048 USA
[8] Natl Inst Hlth NIH, Dept Hematol & Oncol, Bethesda, MD 20814 USA
[9] Inova Schar Canc Inst, Dept Hematol & Oncol, Fairfax, VA 22031 USA
关键词
combined small cell; lung cancer; histology; chemotherapy; molecular changes; CANCER; SCLC;
D O I
10.3390/jcm12030991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Primary lung cancer is the most common cause of cancer-related mortality in the United States (US). Approximately 90% of lung cancers are associated with smoking and the use of other tobacco products. Based on histology, lung cancers are divided into small-cell lung carcinomas (SCLCs) and non-small-cell lung carcinomas (NSCLCs). Most SCLCs are of the pure subtype, while the rare combined SCLCs contain elements of both small-cell and non-small-cell morphologies. This study sought to evaluate the demographics, clinical factors, molecular abnormalities, treatment approaches, and survival outcomes with combined SCLC and NSCLCs. Materials and Methods: Data on 2126 combined SCLC patients was extracted from the Surveillance Epidemiology and End Result (SEER) database from 2000 to 2018. Data extracted for analyses included age, sex, race, tumor size, tumor location, metastasis status, stage at diagnosis, treatment received, and treatment outcomes. Multivariate analysis was performed using Statistical Product and Service Solutions (SPSS) software. Results: The patients had a median age of 68 years; 43.9% of the patients were female and 56.1% were male; 84.5% were White and 11.7% were African Americans. The majority of patients had a poorly differentiated disease at 29.6%; 17% were undifferentiated, 3.2% were moderately differentiated, and 0.8% were well differentiated. Chemotherapy was the most common treatment modality (45.3%); 17% underwent surgery only, 10.3% underwent surgery followed by adjuvant chemotherapy, and 10% underwent radiation after surgery. Five-year cancer-specific survival was 15.2% with surgery alone, and combined surgery and chemotherapy provided the highest percentages (38.3% and 34.7%, respectively). Females had significantly higher 1- and 5-year cancer-specific survival rates compared to males (59.3% and 29.9% vs. 48.0% and 23.7, respectively; p < 0.001). Well-differentiated tumors had significantly higher survival compared to other gradings (p < 0.001). Survival decreased as tumor staging moved distally from localized to regional to distant (p < 0.001). Metastasis to bone, liver, brain, and lung significantly decreased survival in comparison to patients who did not have any metastasis (p < 0.001). Females had significantly shorter survival compared to their counterparts when metastasis was to the bone, brain, or liver (p < 0.001). Multivariate analysis identified male sex (Hazard Ratio (HR) = 1.2), undifferentiated grade (HR = 1.9), regional extent of disease (HR = 1.7), distant extent of disease (HR = 3.7), and metastasis to liver (HR = 3.5) as variables associated with worse survival. Conclusion: Combined SCLC is overall very rare. However, the frequency of presentation with combined SCLC is on the rise, in part due to improvements in diagnostic techniques. Despite advances in therapies, treating combined SCLC is challenging, and novel therapies are not utilized, owing to low rates of targetable mutations. Combined SCLC has higher survival rates if well differentiated.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] COMBINED TREATMENT OF SMALL-CELL LUNG-CARCINOMA
    TRAHTENBERG, AK
    KIM, IK
    DARYALOVA, SL
    FRANK, GA
    BOIKO, AV
    SOVETSKAYA MEDITSINA, 1984, (12): : 39 - 42
  • [2] TREATMENT OF SMALL-CELL CARCINOMA OF THE LUNG
    ZACHARSKI, LR
    LANCET, 1992, 339 (8807): : 1476 - 1477
  • [3] Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study
    Yu, Chen-xi
    Yibulayin, Feiluore
    Feng, Lei
    Wang, Meng
    Lu, Meng-meng
    Luo, Yuan
    Liu, Hui
    Yang, Zhi-cheng
    Wushou, Alimujiang
    BMC CANCER, 2020, 20 (01)
  • [4] Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study
    Chen-xi Yu
    Feiluore Yibulayin
    Lei Feng
    Meng Wang
    Meng-meng Lu
    Yuan Luo
    Hui Liu
    Zhi-cheng Yang
    Alimujiang Wushou
    BMC Cancer, 20
  • [5] SMALL-CELL CARCINOMA OF THE LUNG - TREATMENT IN THE COMMUNITY
    DIGGS, CH
    ENGELER, JE
    PRENDERGAST, EJ
    KRAMER, K
    CANCER, 1992, 69 (08) : 2075 - 2083
  • [6] COMBINED MODALITY APPROACH IN TREATMENT OF INOPERABLE SMALL-CELL ANAPLASTIC CARCINOMA OF LUNG
    OSIEKA, R
    SCHMIDT, CG
    MAKOSKI, HB
    SCHERER, E
    ZEITSCHRIFT FUR KREBSFORSCHUNG UND KLINISCHE ONKOLOGIE, 1977, 89 (01): : 9 - 18
  • [7] Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate
    A B Weiner
    S G Patel
    K A Richards
    R Z Szmulewitz
    S E Eggener
    Prostate Cancer and Prostatic Diseases, 2014, 17 : 286 - 291
  • [8] Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate
    Weiner, A. B.
    Patel, S. G.
    Richards, K. A.
    Szmulewitz, R. Z.
    Eggener, S. E.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2014, 17 (03) : 286 - 291
  • [9] POPULATION-BASED STUDY OF SMALL-CELL LUNG-CANCER - REPLY
    DAVIS, S
    JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (06) : 883 - 884
  • [10] Combined small-cell lung carcinoma
    Qin, Jing
    Lu, Hongyang
    ONCOTARGETS AND THERAPY, 2018, 11 : 3505 - 3511